Pfizer signs licensing deal worth about $6 billion with China's 3SBio for cancer drug

Pfizer and 3SBio Inc. have entered into a licensing agreement valued at approximately $6 billion for the development, manufacturing, and commercialization of SSGJ-707, a drug candidate targeting various cancers. 3SBio will grant Pfizer a global license, excluding China initially, with a potential option for commercialization rights in China. Pfizer also plans a $100 million equity investment in 3SBio.